1-6 of 6
Russell J. Schilder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

Diane M. Da Silva, Danielle M. Enserro, Jyoti S. Mayadev, Joseph G. Skeate, Koji Matsuo, Huyen Q. Pham, Heather A. Lankes, Katherine M. Moxley, Sharad A. Ghamande, Yvonne G. Lin, Russell J. Schilder, Michael J. Birrer, W. Martin Kast
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5621–5630.
https://doi.org/10.1158/1078-0432.CCR-20-0776
Published: 02 November 2020
View article titled, Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Open the PDF for Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) in another window
Includes: Supplementary data
Journal Articles

mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

Seiji Mabuchi, Chiaki Kawase, Deborah A. Altomare, Kenichirou Morishige, Kenjiro Sawada, Masami Hayashi, Masahiko Tsujimoto, Mareo Yamoto, Andres J. Klein-Szanto, Russell J. Schilder, Masahide Ohmichi, Joseph R. Testa, Tadashi Kimura
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5404–5413.
https://doi.org/10.1158/1078-0432.CCR-09-0365
Published: 31 August 2009
View article titled, mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Open the PDF for mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary in another window
Journal Articles

Platinum Resistance: The Role of DNA Repair Pathways

Lainie P. Martin, Thomas C. Hamilton, Russell J. Schilder
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1291–1295.
https://doi.org/10.1158/1078-0432.CCR-07-2238
Published: 03 March 2008
View article titled, Platinum Resistance: The Role of DNA Repair Pathways
Open the PDF for Platinum Resistance: The Role of DNA Repair Pathways in another window
Journal Articles

RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model

Seiji Mabuchi, Deborah A. Altomare, Mitchell Cheung, Lili Zhang, Poulikos I. Poulikakos, Harvey H. Hensley, Russell J. Schilder, Robert F. Ozols, Joseph R. Testa
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4261–4270.
https://doi.org/10.1158/1078-0432.CCR-06-2770
Published: 18 July 2007
View article titled, RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model
Open the PDF for RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model in another window
Journal Articles

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

Russell J. Schilder, Michael W. Sill, Xiaowei Chen, Kathleen M. Darcy, Steven L. Decesare, George Lewandowski, Roger B. Lee, Cletus A. Arciero, Hong Wu, Andrew K. Godwin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5539–5548.
https://doi.org/10.1158/1078-0432.CCR-05-0462
Published: 01 August 2005
View article titled, Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
Open the PDF for Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study in another window
Journal Articles

Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 90Y-labeled Anti-CD20 Monoclonal Antibody

Gregory A. Wiseman, Christine A. White, Thomas E. Witzig, Leo I. Gordon, Christos Emmanouilides, Andrew Raubitschek, Nalini Janakiraman, John Gutheil, Russell J. Schilder, Stewart Spies, Daniel H. S. Silverman, Antonio J. Grillo-López
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3281s–3286s.
Published: 01 October 1999
View article titled, Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a <sup>90</sup>Y-labeled Anti-CD20 Monoclonal Antibody
Open the PDF for Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a <sup>90</sup>Y-labeled Anti-CD20 Monoclonal Antibody in another window